"Antibody therapies for severe gastrointestinal autoimmune diseases"
Gastro-intestinal auto-immune syndromes such as Crohn’s and Refractory Celiac diseases are still poorly addressed by current medications, leading to severe complications, surgery, and degraded life conditions. Calypso Biotech's vision is to give new hope to patients suffering from these diseases by restoring their health and quality of life.
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland, founded in 2013 as a spin-off Merck Serono.
Our mission is to successfully develop first-in-class antibody therapies up to clinical proof-of-concept by leveraging our expertise in immunology and drug development.
Our portfolio consists of two therapeutic antibody programs planned to reach the clinic by 2016-2017.